Plenary Sessions-26/04/2021

Monday, April 26th, 2021

11:00 - 13:00

Poster Discussion

Poster Session 8 - THROMBOTIC RISK ASSESSMENT

Poster Session 9 - BLEEDING COMPLICATIONS

Poster Session 10 - NEW EXPERIMENTAL AND CLINICAL APPROACHES

15:00 - 16:40

Plenary Session 6: Evolving Data for Treatment of VTE in cancer

Chairs: W. Ageno (Italy), G. Soff (USA)

PL-22 - Anticoagulation in Cancer Patients: advantages and disadvantages
A.J. Munoz (Spain)

PL-23 - VTE management: emerging insights from the GARFIELD VTE registry
A.J. Kakkar (UK)

PL-24 - Treatment of VTE in cancer patients: from clinical trials to real life
G. Agnelli (Italy)

PL-25 - VTE in Palliative Care Patients: What do we know?
S. Noble (UK) 

Selected Abstract

OC-14 - Risk factors for recurrence in patients with cancer-associated venous thromboembolism: results from the Hokusai-VTE cancer study
F.T.M. Bosch, T.F. Wang, M. Di Nisio, A. Segers, J. Connors, D. Garcia, F.I. Mulder1,2, J. Weitz, H.R. Büller, M. Carrier, P. Verhamme, M. Grosso, G. Raskob, N. van Es (The Netherlands, USA)

OC-15 - Risk factors of recurrence in cancer-associated venous thromboembolism after discontinuation of anticoagulant therapy: a RIETE-based prospective study
F.X. Lapébie, A. Bura-Rivière, A. Merah, L. Bertoletti, M. Monreal, RIETE investigators (France, Spain)

OC-16 - Apixaban as treatment for cancer-associated venous thrombosis - The CAP study
T.L. Hannevik, J. Brekke, T. Enden, H. Frøen, H. Garresori, W. Ghanima, E.M. Jacobsen, P.Q. Paulsen, A.C. Porojnicu, A.H. Ree, P.M. Sandset, D. Torfoss, E.O. Velle, H.S. Wik, A.E.A. Dahm (Norway)  
     

OC-17 - Rivaroxaban vesus Dalteparin for the Treatment of Cancer-Associated Venous Thromboembolism: the CASTA DIVA Trial
G. Meyer, P. Girard, L.Bertoletti, A. C. Nelson, S. Laporte, I. Mahé, O. Sanchez, P. Mismetti, on behalf the CASTA DIVA Investigators (France) 

16:40 – 17:10

Debate: Incidental VTE: To treat or not to treat?

Chairs: S. Siragusa (Italy), S. Middeldorp (The Netherlands)

YES: M. Di Nisio (Italy)

NO: M. Carrier (Canada) 

17:10 – 17:15

Concluding Remarks